ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients ...

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...

(AP) — Shares of Amgen Inc. fell Thursday over concerns that the Food and Drug Administration's plan to re-examine the safety of anemia drugs could pressure sales of leading anemia treatments Aranesp ...

Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotechnology company promoted its popular Enbrel and ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

A federal judge has denied a request by Johnson & Johnson to temporarily stop Amgen Inc. from selling its anemia drug Aranesp at a discount to doctors who agree to also buy another Amgen product, the ...

BOSTON (CBS.MW) -- Biotechnology giant Amgen Inc. has sent a letter warning health professionals that its anemia drug Aranesp can cause cardiovascular problems when used in high doses. Earlier Friday, ...

As expected, the European Commission gave its marketing nod to Aranesp and Neulasta, the strong-selling U.S. oncology products from Amgen Inc. The company's stock (NASDAQ:AMGN) closed Wednesday at $45 ...

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors In this multicenter, ...

Biotechnology company Amgen Inc. said Wednesday it will cut up to 14 percent of its work force and has lowered its profit guidance because of slimmer than expected sales of its anemia drug Aranesp.